Most Popular
-
1
1 in 3 Koreans live alone, family types becoming diverse
-
2
Korea, Japan finance chiefs vow to tame rampant FX market volatility
-
3
US 'incredibly concerned' about suspected NK-Iran military ties
-
4
K-pop group's manager dismissed for setting up spycam in theater dressing room
-
5
K-pop singer lost consciousness after being hit by foul ball, cancels show
-
6
Korean Muslim YouTuber's plan to build mosque in Incheon goes viral
-
7
Contentious grain bill put directly to plenary meeting for vote
-
8
Why is Apple Pay struggling to get purchase in Korea?
-
9
Yoon's office denies considering liberal figures for key posts
-
10
Seoul says Fu Bao loan 'not going to happen'
SK Bioscience logs record high sales
Annual sales reach 929 billion won; operating profits record 474 billion won
By Kan Hyeong-wooPublished : Feb. 7, 2022 - 17:14
SK Bioscience saw record sales of 929 billion won ($774 million) and operating profits of 474 billion won from last year, on the back of strong businesses in its contract manufacturing of the AstraZeneca and Novavax COVID-19 vaccines, the company said Monday.
Compared to 2020 yearly figures, SK Bioscience’s annual sales and operating profits went up by 311 percent and 1,158 percent, respectively.
About half of the annual numbers came in the fourth quarter alone as the company logged 451 billion won in sales and 254 billion won in operating profits during the period.
The biopharmaceutical firm said it will look to continue to build on the growing momentum as it plans to complete the development of its coronavirus vaccine candidate GBP510, secure more vaccine platforms and expand infrastructures this year.
SK Bioscience’s GBP510 is currently undergoing the third and last phase of clinical trials.
Compared to 2020 yearly figures, SK Bioscience’s annual sales and operating profits went up by 311 percent and 1,158 percent, respectively.
About half of the annual numbers came in the fourth quarter alone as the company logged 451 billion won in sales and 254 billion won in operating profits during the period.
The biopharmaceutical firm said it will look to continue to build on the growing momentum as it plans to complete the development of its coronavirus vaccine candidate GBP510, secure more vaccine platforms and expand infrastructures this year.
SK Bioscience’s GBP510 is currently undergoing the third and last phase of clinical trials.
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240418181020)
![[Today’s K-pop] Zico drops snippet of collaboration with Jennie](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/04/18/20240418050702_0.jpg&u=)